Evidence Intelligence™
- EvidenceScore™
- Moderate
- Score 69 · Based on 2 studies
- ImpactScore™
- 93
- Very Positive
- ConsistencyScore™
- 100
- consistent
Estudios de apoyo: Basado en 2 estudios
Add to Evidence TrackerResumen de Investigación
Analyzed using Evidence Intelligence™
Semaglutide reduces insulin doses in type 1 diabetes
Última actualización 22 de agosto de 2026
Key finding
There was a significant 22.6% reduction in TDD (95% CI -28.3 to -17.0).
This study evaluated the effects of semaglutide on insulin doses and weight loss in adults with type 1 diabetes and obesity, finding significant reductions in insulin doses.
Quick read
Study at a glance
The essential study design details in one scan.
EvidenceScore™
Moderate
Study type
RCTs
Follow-up
Medium-Term (3–12 mo)
Risk of bias
High Risk
Guarda investigacion, organiza estudios y vuelve a encontrar evidencia importante rapidamente.
Plain-language summary
What this paper says
A plain-language read of the study’s main message and where it applies.
Study focus
This study evaluated the effects of semaglutide on insulin doses and weight loss in adults with type 1 diabetes and obesity, finding significant reductions in insulin doses.
Clinical relevance
This study highlights the potential of semaglutide as a treatment option for adults with type 1 diabetes and obesity, suggesting it may help manage insulin requirements and dietary intake. These findings could lead to improved diabetes management strategies and better health outcomes for this population.
Keep in mind
Limited sample size may affect generalizability. Short duration of the study may not capture long-term effects. Lack of significant changes in the placebo group limits comparative analysis.
Published in
Referencia de la Revista
Publication details and source links for this paper.
Kagan EK, Halis KA, Davida K, et al. Semaglutide Treatment in Adults with Type 1 Diabetes and Obesity: Insulin Dose Reduction and Weight Loss. Diabetes Care. 2026;49(5):718-723. doi:10.2337/dc25-2249
Efectos Principales
Total daily insulin dose (TDD) reduced by 22.6% (p=0.001).
Bolus insulin dose decreased by 30.5%.
Basal insulin dose decreased by 15.6%.
Daily carbohydrate intake decreased by 30 g.
Evidence network
How this study fits
Understand where this research contributes within the broader evidence network.
Evidence Context
This study contributes evidence to Semaglutide and Basal insulin dose, Bolus insulin dose, Carbohydrate intake, and 1 more.
This study contributes evidence to
Primary intervention
Semaglutide
Primary outcomes
- Basal insulin dose
- Bolus insulin dose
- Carbohydrate intake
Evidence topics
Primary intervention
Primary outcomes
Evidence relationships
Intervention and outcome relationships this study adds to the evidence network.
4
Evidence pairs
4
Relationships
2
Evidence topics
contributes_evidence
Editorial context
Why this study matters
See why this paper is useful beyond its individual results.
Evidence network role
This section describes how the study fits into the current evidence network. It does not determine whether an intervention works on its own.
Moderate contributionModerate confidenceNetwork score: 65
2
Related topics
4
Evidence pairs
232
Related studies
High relevance in at least one topic
Why it is useful
- Contributes to 4 evidence relationships
- Includes primary outcome data
- Linked to 2 direct semantic evidence topics
Topic contributions
Evidence topic
Contributes evidence
Evidence topic
Contributes evidence
Agrega evidencia relacionada a tu Evidence Tracker
Guarda estudios y paginas de evidencia, organiza tu Evidence Tracker y manten en un solo lugar la investigacion que te importa.
Evidencia principal
Relación de evidencia
GLP-1 Receptor Agonists and Insulin Resistance
Evidencia relacionada
Tema de evidencia
Adverse Events and Safety
Guardar evidencia
Tema de evidencia
GLP-1 Receptor Agonists
Guardar evidencia
Core evidence
Study findings
The primary outcomes reported in this study.
Evidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 85
- Very Positive
- ConsistencyScore™
- unclear
- Not enough independent studies
Estudios de apoyo: Basado en 1 estudio
Add to Evidence TrackerTotal daily insulin dose
Semaglutide → Total daily insulin dose
Semaglutide → Total daily insulin dose
Evidence Intelligence™
- EvidenceScore™
- Moderate
- Score 69 · Based on 2 studies
- ImpactScore™
- 100
- Very Positive
- ConsistencyScore™
- 100
- consistent
Estudios de apoyo: Basado en 2 estudios
Add to Evidence TrackerEvidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 100
- Very Positive
- ConsistencyScore™
- unclear
- Not enough independent studies
Estudios de apoyo: Basado en 1 estudio
Add to Evidence TrackerEvidence Library
Build your evidence library
Save research, organize studies, and quickly find important evidence again.
La Evidencia Sugiere
- Semaglutide reduced total daily insulin dose by 22.6%.
- Bolus insulin dose decreased by 30.5%.
- Carbohydrate intake reduced from 137 g to 107 g.
A quién se aplica
- Adults aged 18 and older with type 1 diabetes.
- Individuals with obesity as defined by clinical criteria.
Tener en Cuenta
- Results may not apply to younger populations or those without obesity.
- Further studies are needed to confirm long-term effects.
- The study's findings are based on a specific population and may not generalize to all individuals with type 1 diabetes.
Entre Líneas
- Limited sample size may affect generalizability.
- Short duration of the study may not capture long-term effects.
- Lack of significant changes in the placebo group limits comparative analysis.
Evidence Library
Build your evidence library
Save research, organize studies, and quickly find important evidence again.
Connected Evidence
Explore related studies, evidence collections, and research questions.
Relationships organized using the Dediabetes Evidence Intelligence™ framework.
This study contributes to evidence on GLP-1 Receptor Agonists and Basal insulin dose, GLP-1 Receptor Agonists and Insulin Resistance.
Relaciones de evidencia relacionadas
Explore in Evidence ExplorerThis study contributes to the evidence on the following intervention-outcome relationships.
Medications
GLP-1 Receptor Agonists → Basal insulin dose
Medications
Evidence Intelligence™
- EvidenceScore™
- Moderate
- Score 69 · Based on 2 studies
- ImpactScore™
- 93
- Very Positive
- ConsistencyScore™
- 100
- consistent
Estudios de apoyo: Basado en 2 estudios
View evidenceMedications
GLP-1 Receptor Agonists → Insulin Resistance
Medications
Evidence Intelligence™
- EvidenceScore™
- Moderate
- Score 69 · Based on 2 studies
- ImpactScore™
- 100
- Very Positive
- ConsistencyScore™
- 100
- consistent
Estudios de apoyo: Basado en 2 estudios
View evidenceIncluido en estas colecciones de evidencia
Curated evidence collections and hubs this study is part of.
Basal insulin dose Evidence Hub
All studies measuring Basal insulin dose
2 studies
outcome_hubMeasures Basal insulin dose as a key outcome.
GLP-1 Receptor Agonists Evidence Hub
All studies on GLP-1 Receptor Agonists
2 studies
intervention_hubContributes to GLP-1 Receptor Agonists evidence base.
Insulin Resistance Evidence Hub
All studies measuring Insulin Resistance
2 studies
outcome_hubMeasures Insulin Resistance as a key outcome.
Explora más en Evidence Explorer
Jump to pre-filtered views in Evidence Explorer.
All studies on Semaglutide and Basal insulin dose
Intervention: SemaglutideOutcome: Basal insulin dose
2 results
All studies on Semaglutide and Total daily insulin dose
Intervention: SemaglutideOutcome: Total daily insulin dose
2 results
All studies on Semaglutide
Intervention: Semaglutide
2 results
All studies measuring Basal insulin dose
Outcome: Basal insulin dose
2 results
All studies measuring Total daily insulin dose
Outcome: Total daily insulin dose
2 results
Questions answered by this study
Generated from the study's connected evidence using Evidence Intelligence™.
Does GLP-1 Receptor Agonists improve insulin resistance?
Strong Evidence
GLP-1 Receptor Agonists appears to improve Insulin Resistance.
ConsistencyScore™: Results are generally consistent across studies.
Ranked evidence signals
- 1
Total daily insulin dose
EvidenceScore™ Moderate | EvidenceScore™ 69.0 | strong positive | ConsistencyScore™ Consistent | 1 study
Why this answer: This answer is based on 7 supporting studies with generally consistent results and a positive effect signal.
Limitations
- Population details are unavailable.
Does Semaglutide improve basal insulin dose?
Moderate Evidence
Semaglutide appears to improve Basal insulin dose.
ConsistencyScore™: Results are consistent across studies.
Ranked evidence signals
- 1
Basal insulin dose
EvidenceScore™ Moderate | EvidenceScore™ 69.0 | strong positive | ConsistencyScore™ Consistent | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
- Only one supporting study is available.
- Population details are unavailable.
Does Semaglutide improve bolus insulin dose?
Emerging Evidence
Semaglutide appears to improve Bolus insulin dose.
ConsistencyScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
- 1
Bolus insulin dose
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | strong positive | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
- Only one supporting study is available.
- Consistency cannot yet be determined.
- Population details are unavailable.
Does Semaglutide improve carbohydrate intake?
Emerging Evidence
Semaglutide appears to improve Carbohydrate intake.
ConsistencyScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
- 1
Carbohydrate intake
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | strong positive | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
- Only one supporting study is available.
- Consistency cannot yet be determined.
- Population details are unavailable.
Next steps
Continue your research
Choose a next path through related evidence topics, Evidence Explorer views, and research summaries.
Evidence topics
Follow the topics this study contributes to.
Explore in Evidence Explorer
Open broader Evidence Explorer views for this relationship.
Related research
Read related research summaries.
Semaglutide may reduce cardiovascular events in non-diabetic patients.Oral semaglutide reduces cardiovascular events in type 2 diabetesHigher semaglutide doses improve glucose control in type 2 diabetesNovel Semaglutide Injection Shows Non-Inferior Glycemic ControlOral semaglutide may improve cardiovascular event prevention in type 2 diabetes.
Sin anuncios. Sin rastreo.
Centrada en la evidencia, no en la publicidad.
Segura y privada
Tus datos siempre están protegidos.
Siempre al día
Se agregan nuevos estudios todos los días.